---
title: "CanSino Biologics Inc. (06185.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/06185.HK.md"
symbol: "06185.HK"
name: "CanSino Biologics Inc."
industry: "Biotechnology"
---

# CanSino Biologics Inc. (06185.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.cansinotech.com.cn](https://www.cansinotech.com.cn) |

## Company Profile

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the preven...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: C (0.50)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 23 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 28.50% |  |
| Net Profit YoY | 80.48% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.53 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8.27B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.05B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.84% | D |
| Profit Margin | -14.62% | D |
| Gross Margin | 82.15% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 28.50% | A |
| Net Profit YoY | 80.48% | A |
| Total Assets YoY | -9.88% | E |
| Net Assets YoY | -3.95% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -684.22% | E |
| OCF YoY | 28.50% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.13 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 32.46% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - CanSino Biologics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.84%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-14.62%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "82.15%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "28.50%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "80.48%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.88%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.95%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-684.22%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "28.50%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "32.46%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -53.13 | 58/70 | - | - | - |
| PB | 1.53 | 9/70 | 2.14 | 1.71 | 1.57 |
| PS (TTM) | 7.94 | 18/70 | 11.71 | 9.53 | 8.66 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-05T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 75% |
| Overweight | 1 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.46 |
| Highest Target | 65.32 |
| Lowest Target | 41.37 |

## References

- [Company Overview](https://longbridge.com/en/quote/06185.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/06185.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/06185.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.